Delineating and modulating the gliotic changes occurring after spinal cord injury

Information

  • Research Project
  • 10216278
  • ApplicationId
    10216278
  • Core Project Number
    P20GM121310
  • Full Project Number
    5P20GM121310-05
  • Serial Number
    121310
  • FOA Number
    PAR-14-035
  • Sub Project Id
    7743
  • Project Start Date
    9/1/2017 - 7 years ago
  • Project End Date
    7/31/2022 - 3 years ago
  • Program Officer Name
  • Budget Start Date
    8/1/2021 - 4 years ago
  • Budget End Date
    7/31/2022 - 3 years ago
  • Fiscal Year
    2021
  • Support Year
    05
  • Suffix
  • Award Notice Date
    7/19/2021 - 4 years ago
Organizations

Delineating and modulating the gliotic changes occurring after spinal cord injury

Injury to the central nervous system (CNS) by disease or trauma causes a cascade of cellular responses that must occur to restore the delicate microenvironment necessary for function of the CNS. However, the changes caused to CNS tissue by these cellular responses may create an environment that is not permissive to functional regeneration. For patients, this results in permanent loss or aberration of function. In the case of spinal cord injury (SCI), patients often develop allodynia and other pain syndromes in addition to motor impairment. We are seeking to gain a better understanding of the cellular processes that occur following SCI that cause impairment and to develop therapies of small molecules and optogenetically responsive cells to promote functional repair of neural circuits. We are specifically interested in the changes that occur in activated astrocytes and the alterations in the expression of glycans following SCI that occur during gliosis. We will develop a model of reactive astrogliosis using precursor derived astrocytes that can be used to delineate the signaling mechanisms responsible for astrogliosis. We hypothesize that extensive changes in glycosylation occur during astrogliosis that mediate the injury response after SCI and will test this by characterizing large scale changes in glycosylation after SCI. Glycomics is an advancing field and this would be the first study documenting the changes in glycosylation in the CNS after an injury. Our second and third aims are more translational in nature and will develop therapeutics that both mitigate inhibitory signals after SCI and provide positive cues to stimulate regeneration. Chondroitin sulfate (ChS) is a glycan known to inhibit regeneration and we hypothesize that compounds can be identified that bind to and mask ChS from inhibitory receptors. To provide positive stimuli, we will develop and test an optogenetic system that we hypothesize can be used to control the behavior of cells (proliferation, gene expression etc) post-implantation by non-invasive means.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    P20
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
    131191
  • Indirect Cost Amount
    50397
  • Total Cost
  • Sub Project Total Cost
    181588
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIGMS:181588\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZGM1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    UNIVERSITY OF WYOMING
  • Organization Department
  • Organization DUNS
    069690956
  • Organization City
    LARAMIE
  • Organization State
    WY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    820712000
  • Organization District
    UNITED STATES